[CAS NO. 166095-21-2] BMS-191095
PRODUCTS SPECIFICATIONS [166095-21-2]
DESCRIPTION [166095-21-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 408.88 |
| Molecular Formula | C22H21ClN4O2 |
| SMILES | CC(O1)(C)[C@H](O)[C@@H](N(CC2=NC=CN2)C3=CC=C(Cl)C=C3)C4=C1C=CC(C#N)=C4 |
Summary
In Vitro
BMS-191095 (50 μmol/L) induces mitochondrial depolarization of vascular smooth muscle (VSM) cells from SD rats
[1]
.
BMS-191095 (10-100 μmol/L) dose-dependently induces vasodilation in endothelium denuded cerebral arteries
[1]
.
BMS-191095 (50 μmol/L) increases the frequency of calcium sparks in VSM cells
[1]
.
BMS-191095 (0-1500 μM) inhibits human platelet aggregation induced by collagen and thrombin with IC
50
values of 63.9 and 104.8 μM, respectively
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BMS-191095 (2.5 or 25 μg; intraventricular infusion, 30 min/60 min/24 hours before the induction of ischemia, once) reduces neuronal damage in rats with transient focal cerebral ischemia [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Wistar rats with the induction of ischemia induced by middle cerebral artery occlusion (MCAO) [3] |
| Dosage: | 2.5 or 25 μg |
| Administration: | Intraventricular infusion; 30 min/60 min/24 hours before the induction of ischemia, once |
| Result: | Reduced total infarct volume in rats with of pretreat dose of 25 mg and 24 h before MCA. Induced a rapid mitochondrial depolarization. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 244.57 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4457 mL | 12.2285 mL | 24.4571 mL |
| 5 mM | 0.4891 mL | 2.4457 mL | 4.8914 mL |
| 10 mM | 0.2446 mL | 1.2229 mL | 2.4457 mL |
References
- [1] Katakam PV, et al. Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307(4):H493-503.
- [2] Cho MR, et al. BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels. Arch Pharm Res. 2005 Jan;28(1):61-7.
- [3] Mayanagi K, et al. The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007 Feb;27(2):348-55.
